The new office reinforces InterSystems commitment to Indonesia as a strategic growth market in Southeast Asia, enabling closer collaboration with customers, partners, and government stakeholders to address the country’s evolving data platform, interoperability, and digital infrastructure needs.

Indonesia’s digital economy is expanding rapidly, driven by strong growth in cloud computing, data platforms, and artificial intelligence (AI). Organizations across sectors are increasingly focused on integrating fragmented systems, unlocking real-time insights, and improving operational resilience through data-driven strategies.
This transformation is creating significant market opportunities. Across industries, demand is rising for high-performance data platforms that can support real-time analytics, seamless system integration, and AI-enabled decision-making.

InterSystems technologies, including the InterSystems IRIS® Data Platform and InterSystems IntelliCare™ unified healthcare information system, are deployed by organizations across Indonesia. The company works with enterprises, system integrators, and digital partners across financial services, logistics, and healthcare to enable interoperability, streamline operations, and support the adoption of AI.

“Indonesia is at an inflection point where organizations are looking to turn increasing volumes of data into actionable insight. There is a growing need for reliable, interoperable, and real-time data platforms that can support innovation at scale. The opening of our new Jakarta office reflects our long-term commitment to Indonesia and allows us to work more closely with customers and partners to help turn their ambitions into outcomes.” said Luciano Brustia, Regional Managing Director, Asia Pacific, InterSystems.

Priorities for the Expanded Local Presence

Through its expanded local presence, InterSystems is set to deepen engagement with its growing Indonesian customer base by delivering localized expertise and accelerating implementation timelines. The company will further strengthen collaboration with partners across financial services, supply chain, and healthcare sectors, while actively supporting national priorities around data integration, interoperability, and digital resilience.

InterSystems solutions address key challenges across industries, including data silos, fragmented systems, and the increasing need for real-time analytics to support operational and strategic decision-making. By enabling seamless data exchange and high-performance analytics, InterSystems helps organizations build more connected and resilient digital ecosystems.

InterSystems, a creative data technology provider powering more than one billion health records globally, today announced that its electronic health record (EHR) solutions have been certified as Class IIa Medical Devices under Regulation (MDR) certification under Regulation (EU) 2017/745. This approval marks the first fully unified AI-native EHR to achieve MDR Class IIa certification in the European Union.

This certification demonstrates that InterSystems AI-native EHR meets stringent EU safety and quality standards. This key milestone has significant implications for how healthcare organizations can responsibly scale AI while building confidence among healthcare providers and regulators.

InterSystems has secured MDR certification for InterSystems IntelliCare™, a next-generation EHR architected with native artificial intelligence capabilities, and InterSystems TrakCare®, a unified healthcare information system used by leading healthcare systems globally. Built on TrakCare’s proven interoperability foundation, InterSystems IntelliCare differentiates itself by delivering AI capabilities that are fundamentally designed into the platform’s data layer, rather than bolted on as third-party applications.

“Healthcare organizations are rightfully demanding that AI be more than just an experimental add-on,” said Don Woodlock, President, InterSystems. “By securing the EU’s first MDR certification for an AI-native EHR, we are establishing a standard that AI should be at the core of all healthcare applications”.

By moving beyond fragmented AI add-ons, InterSystems IntelliCare provides organizations with simplified oversight for their own governance, and clinicians with tools designed to reduce workload and burnout. The platform delivers instant patient summaries, AI‑driven clinical documentation, full chat experiences and intelligent workflows that maintain a critical “human-in-the-loop” safeguard. Features such as ambient clinical orchestration automatically capture, structure and save clinical data in real-time and suggest clinical documentation and orders for clinician approval. InterSystems IntelliCare also seamlessly connects with existing health IT infrastructures, leveraging InterSystems deep history in integration and data management capabilities.

Japan’s healthcare sector continues to face growing strain as the country’s aging population increases demand for medical services. Medical costs have risen beyond 48 trillion yen annually, while healthcare providers are dealing with staffing shortages, financial pressures, and broader sustainability concerns within the social security system. At the same time, medical data required for advanced clinical research remains insufficiently standardized and fragmented across institutions, limiting broader utilization. Fujitsu and IBM Japan said easing the administrative burden on healthcare workers and enabling more efficient use of medical data across organizations will be essential for improving care delivery. Under the collaboration, the companies will jointly promote operational efficiency initiatives while supporting medical DX measures encouraged by the Japanese government. Their sovereign cloud platform will serve as a common foundation for healthcare applications provided by both companies, enabling medical institutions to adopt cloud-based systems with stronger control over data management and security.

The companies also plan to integrate and jointly utilize their AI technologies for the healthcare industry. With consent from healthcare providers and patients, Fujitsu and IBM Japan aim to securely combine data from multiple medical institutions in Japan to improve clinical and operational workflows. Planned use cases include AI support for preparing clinical and nursing reports as well as streamlining DPC coding processes linked to medical fee claims. The collaboration is also exploring initiatives connected to drug discovery and clinical development, including identifying patients eligible for clinical trials and improving research efficiency. By expanding cooperation with university hospitals, national centers, and other medical institutions, the companies intend to validate healthcare data and AI applications before phased deployment. Medical AI will also support future patient-centric services covering appointment booking, treatment processes, and post-care follow-up.

The launch follows increasing use of artificial intelligence tools within hospital pharmacy environments. Bluesight’s 2026 research found that 24% of pharmacy leaders currently use AI every day, while 35% of diversion professionals already depend on tools such as ChatGPT and Microsoft Copilot to review controlled substance data. Prism Assistant was developed specifically for diversion monitoring workflows rather than general-purpose AI applications. The company stated that the platform functions entirely within its secure infrastructure, uses integrated ControlCheck data sources, and aligns with Google’s Secure AI Framework (SAIF). “Demand for generative AI in diversion monitoring is already here,” said Kevin MacDonald, CEO and co-founder of Bluesight. “But many teams are using tools that weren’t built for sensitive healthcare data or diversion workflows. Prism Assistant delivers the speed they need while keeping data secure and grounded in the workflows they already trust.”

Using Prism Assistant, diversion teams can request reports, graphs, and evidence-backed responses related to provider behavior and controlled substance trends in less than a minute. Bluesight said this allows staff to spend more time on higher-priority investigations, regulatory compliance activities, and diversion confirmation processes instead of manually assembling data. Twenty health systems are already deploying the assistant within ControlCheck for peer comparisons, executive reporting, and staff investigation analysis. Reported outcomes include recurring reports being completed 96% faster, pre-investigation triage reduced from three hours to around 10 minutes, and detailed variance analysis shortened from 30 minutes to under a minute. Bluesight also confirmed the Hospital AI Platform will expand into PrivacyPro later this year while the company develops agentic AI capabilities capable of handling multi-step workflows independently.

Skilltrade’s programs include live instruction, certification preparation, hands-on lab work, and hybrid learning models tailored for workforce partners and adult learners. By incorporating these training pathways directly into ShiftMed’s platform, healthcare providers can expand workforce development efforts using both internal staff and external candidates. “Healthcare organizations require more than immediate labor capacity; they need strategic solutions that architect a sustainable pipeline,” said Todd Walrath, CEO of ShiftMed. “By partnering with Skilltrade, we are giving our clients the ability to not only optimize the workforce they have today but to actively engineer the credentialed workforce they need to solve the workflow challenges of tomorrow.”

Under the partnership, health systems will be able to identify workforce gaps and transition candidates into certified clinical roles through cohort-based training programs. These programs are designed to convert applicant pools into credentialed float staff while also supporting employee advancement into roles such as medical assistants, sterile processing technicians, surgical technologists, and patient care technicians. Training delivery options include onsite, hybrid, and online formats, alongside access to employer-sponsored education programs, workforce grants, and apprenticeship pathways. The Allied Health initiative also aligns with ShiftMed’s broader efforts to reduce dependence on contract labor, improve retention through career mobility, strengthen workforce stability, and support healthcare delivery operations. “Healthcare employers are navigating a complex and fragmented workforce ecosystem,” said Jason Aubrey, CEO of Skilltrade. “Our role is to simplify that complexity, bringing AI-enabled training, funding navigation, and workforce partnerships together into one coordinated solution. Partnering with ShiftMed allows us to deliver that value at scale.”

The telesurgery demonstration took place during the Annual Scientific Congress 2026 of The Royal Australasian College of Surgeons (RACS), held in Perth between April 30 and May 3, 2026. The live procedure highlighted the ability of robotic surgery platforms to enable advanced surgical interventions across international borders while maintaining operational precision and responsiveness. The surgical system combined ultra-low latency connectivity, high-definition visualisation, and precise robotic instrument control through the SSI Mantra and MantrAsana platforms.

Dr. Mohit Bhandari, President, IRCAD India and Founder & Director of Mohak Bariatric and Robotic Surgery Centre, Indore, said, “This telesurgical milestone demonstrates that distance is no longer a barrier in delivering advanced surgical care. Performing a complex robotic gastrojejunostomy from Perth on a patient in Indore with such precision validates the robustness of the made in India SSI Mantra platform and the transformative capabilities of MantrAsana. This is not just a technological achievement, it is a new model for global, collaborative, patient centric healthcare.”

Speaking about the achievement, SS Innovations Founder, Chairman and CEO Dr. Sudhir Srivastava said, “I would like to congratulate Dr. Mohit and the entire team on successfully achieving this landmark 10,000-kilometre telesurgery between Australia and India. This milestone marks a significant step forward in advancing connected healthcare globally and reflects our core vision of making advanced robotic surgery accessible across geographies and healthcare systems. Powered by our indigenous SSI Mantra and MantrAsana platforms, this achievement reinforces India’s growing leadership in surgical innovation and demonstrates the potential of technology to enable seamless, borderless care delivery. We remain committed to our vision of democratizing robotic surgery and expanding access to high-quality, technology-enabled healthcare worldwide.” The successful demonstration drew attention from surgeons, clinicians, and delegates attending the congress, underlining the growing role of robotic telesurgery in expanding access to specialised surgical expertise worldwide.

The partnership integrates Lexitas’ ophthalmology-focused strengths built over more than 15 years, including an extensive investigator network and an established reading center with NAMSA’s global MedTech development infrastructure. By aligning these capabilities, the companies intend to streamline processes for device innovators, enabling coordinated execution from early-stage development through commercialization. The model eliminates fragmented vendor structures, offering sponsors centralized oversight and continuity across each phase of development.

Rather than operating through traditional subcontracting or referral arrangements, the two organizations will function as a unified team under a shared operating framework. Lexitas’ clinical specialists, including those focused on imaging, medical monitoring, and site strategy, will be embedded within NAMSA’s program management systems. This approach is supported by a common technology platform and unified quality management processes, providing sponsors with a single point of accountability and visibility across their programs.

The NAMSA and Lexitas collaboration is structured to deliver end-to-end support spanning preclinical development, biocompatibility assessments, investigational device exemption (IDE) processes, pivotal trials, regulatory submissions, and commercialization. It also leverages Lexitas’ network of more than 700 investigator sites and specialized programs such as BCVA certification. Combined with NAMSA’s expertise in device-specific trial design, regulatory strategy, and global CRO operations across the U.S., Europe, and Asia-Pacific, the partnership aims to enhance execution efficiency and reduce coordination risks for sponsors developing ophthalmic technologies.

In a statement, Brian Smith, Chief Executive Officer, NAMSA, said: “Ophthalmic device sponsors have asked us for something the market hasn’t been able to deliver in a coordinated way: deep device-specific expertise across the full development lifecycle, paired with specialized ophthalmic clinical execution. This partnership with Lexitas allows us to offer exactly that. NAMSA brings the end-to-end development platform ophthalmic device innovators’ need Lexitas brings the unparalleled ophthalmic expertise depth that elevates the clinical stage. Together, we’re giving sponsors a rare combination: world-class device development under one contract, with the ophthalmic specialization to execute at the highest level.”

Jeanne Hecht, Chief Executive Officer, Lexitas, added: “NAMSA’s global MedTech development platform is a powerful complement to what Lexitas has built in ophthalmology. By embedding our ophthalmic experts across site strategy, imaging, and medical oversight within NAMSA’s operating model, the partnership enables sponsors to execute highly specialized ophthalmic trials with greater confidence and consistency. Together, NAMSA’s medical device expertise and Lexitas’ ophthalmology focus deliver a truly integrated approach that drives value for sponsors and meaningful impact for patients.”

Established in 1983 and headquartered in Istanbul, SEM Plastik is a leading regional plastics manufacturer with a strong legacy as one of Türkiye’s pioneers in sustainable packaging and, more recently, advanced medical manufacturing. SEM Plastik continues to expand its global presence, building on more than 25 years of engineering excellence.

To support this transition into medical manufacturing, SEM Plastik selected Husky as a long term supplier, recognizing the value of the company’s ICHORTM integrated medical system technology platform, and comprehensive service offering. As an early adopter, SEM Plastik invested in a complete solution designed to deliver consistent quality, operational efficiency, and regulatory compliance from day one.

High End Quality and Regional Impact

Through its SEM BIOTECH division and under its Vacusem brand, SEM Plastik has entered the medical components market and operates one of the most precise and high-capacity vacuum blood collection tube production lines in the world, with an annual production capacity of 500 million tubes, delivering the highest quality standards in Türkiye.

Vacusem tubes are fully automatically manufactured in an ISO 8 cleanroom environment and packaged under the highest hygiene standards, using best-in-class chemical formulations and components. The production is designed to meet European Union market standards, with a strong focus on export-oriented growth. This investment makes a strong contribution to Türkiye’s high value-added and high-technology exports.

“Diversifying into medical manufacturing required a trusted supplier and a proven technology platform. We are proud to serve the region with best in class blood collection tubes, and Husky’s support as an early adopter partner was essential in helping us turn this ambition into a successful and sustainable operation”, said Yavuz Eroğlu, SEM Plastik’s Owner-Chairman and President of PAGEV, the Turkish Plastic Packaging Manufacturers Association.

The collaboration supports Türkiye’s emergence as a reliable producer of high quality blood collection tubes, strengthening local supply chains while establishing a foundation for continued innovation and market expansion.

System Level Solution Enables Rapid Market Entry

Husky’s solution combines the ICHOR™ integrated medical system, advanced Schöttli Medical Molds, and Advantage+Elite™ proactive monitoring support, enabling SEM Plastik to establish a scalable, high performance production platform for blood collection tubes. The integrated system approach reduces operational complexity while delivering enhanced throughput, reduced material waste, and consistent part quality.

“We are proud to support SEM Plastik’s growth with the deployment of the ICHOR™ system, the fastest platform solution to produce blood collection tube in the market. By combining speed, precision, and full system integration, we are helping SEM Plastik establish a world class medical production platform in Türkiye”, said Thomas Bontempi, Husky’s General Manager Medical Business.

Husky’s advanced technology contributes to reduced cycle times and improved efficiency, while full traceability and process stability support compliance with stringent international medical standards. Additionally, dedicated training programs for running the system have been delivered to support medical injection molding and process optimization, enabling long-term operational excellence.

As policymakers and industry leaders prepare to gather at Interclean 2026, new insights highlight the significant economic and societal contribution of Europe’s tissue sector – an often overlooked but essential pillar of daily life, hygiene, and public health.

According to ETS’ latest socioeconomic impact analysis, the tissue industry:

• Supports over 421,000 jobs across Europe, with employment extending far beyond manufacturing into retail, logistics, and services
• Generates €19.7 billion in annual revenue, highlighting the sector’s role in Europe’s industrial and economic ecosystem
• Delivers 8.2 million tonnes of essential tissue products each year, supporting hygiene in homes, healthcare, and public spaces
• Plays a critical role in hygiene standards, particularly in healthcare settings, public facilities, and high-traffic environments

At a time when Europe is navigating complex discussions around sustainability, public health, and industrial policy, these findings underscore the importance of a balanced, evidence-based approach to hygiene solutions.

“Tissue products are a cornerstone of modern hygiene systems,” said Carlos Reinoso, Director General of the European Tissue Symposium (ETS). As policymakers consider future regulations, it is essential to recognise both the economic contribution of our sector and the critical role tissue plays in protecting public health. Decisions must be grounded in science, lifecycle thinking, and real-world usage.”

The findings contribute to the broader sustainability debate by highlighting the importance of lifecycle thinking, hygiene performance, and practical implementation.

Meet ETS at Interclean 2026

ETS will be present at Interclean 2026, engaging with policymakers, industry stakeholders, and media to discuss the implications of the study for Europe’s regulatory and sustainability landscape.

Journalists and attendees are invited to connect with ETS on-site to explore:

• The full socioeconomic impact of the tissue industry
• The role of tissue in maintaining hygiene and public health
• The importance of evidence-based policymaking in sustainability discussions

Media Opportunities

• On-site meetings with ETS representatives
• Access to key data and insights from the socioeconomic impact study
• Expert commentary on hygiene, sustainability, and regulatory developments

To arrange a meeting or interview, please contact:
Nadia Del Rio | press@europeantissue.com

Combining strong electronics manufacturing capabilities with biomedical engineering expertise, Taiwan has developed a dynamic MedTech ecosystem that continues to draw attention from global healthcare distributors, hospital procurement teams, and system integrators seeking scalable healthcare solutions.

Against this backdrop, Medical Taiwan 2026, organized by TAITRA, will take place June 25–27, 2026, at Taipei World Trade Center (TWTC) Exhibition Hall 1 in Taipei. The exhibition will bring together Taiwanese medical device manufacturers, healthcare technology innovators, and international buyers, offering a comprehensive platform for exploring new technologies and building cross-border partnerships.

Over the past decade, Taiwan has steadily strengthened its position in the global medical device industry. Its well-established electronics sector provides a strong technological foundation for developing advanced healthcare solutions that integrate hardware, software, and data-driven systems. Many Taiwanese companies are particularly known for integrating Information and Communication Technology (ICT) with healthcare applications, supporting the development of smart hospital infrastructure, AI-assisted diagnostics, and connected medical devices designed for modern clinical environments.

Organized by the Taiwan External Trade Development Council (TAITRA), Medical Taiwan 2026 will highlight several major trends shaping the healthcare industry, including digital transformation, aging populations, and the growing demand for efficient healthcare delivery systems. This year’s exhibition focuses on three key themes:

• Innovative Care – Innovations in community and home healthcare solutions
• Smart Healthcare – Driving the future of digital and connected health
• Medical Supplies Hub – Comprehensive solutions for premium medical devices and consumables

Visitors will be able to explore a wide range of technologies, including AI-assisted medical imaging, remote patient monitoring solutions, rehabilitation and assistive devices for aging populations, hospital information system integration, and medical components supported by Taiwan’s strong OEM/ODM manufacturing capabilities.

In addition to product showcases, the exhibition will facilitate business collaboration through One-on-One Procurement Meetings organized by TAITRA, allowing international buyers to connect directly with Taiwanese suppliers based on their sourcing needs.

Medical Taiwan 2026 offers the ideal platform to discover new products, explore procurement opportunities, and stay ahead of global healthcare trends. From June 25 to 27 at TWTC Exhibition Hall 1 in Taipei, the exhibition will bring together industry leaders and innovators shaping the future of healthcare.

Register now to secure your spot to visit